Carlos Manuel de Castro, MD

Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 25158 Morris Bldg, Durham, NC 27710
Phone (919) 684-8964
Email address decas003@mc.duke.edu

Clinical research projects have focused on new and innovative treatments for myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, adult leukemias, and lymphomas

Education and Training

  • Fellow In Hematology Oncology, Medicine, Duke University, 1988 - 1991
  • Resident, Medicine, University of Texas at Dallas, 1985 - 1988
  • M.D., University of Texas at Dallas, 1985

Publications

Brander, D, Rizzieri, D, Gockerman, J, Diehl, L, Shea, TC, Decastro, C, Moore, JO, and Beaven, A. "Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma." Leuk Lymphoma 54, no. 12 (December 2013): 2627-2630.

PMID
23488610
Full Text

Greenberg, PL, Attar, E, Bennett, JM, Bloomfield, CD, Borate, U, De Castro, CM, Deeg, HJ, Frankfurt, O, Gaensler, K, Garcia-Manero, G, Gore, SD, Head, D, Komrokji, R, Maness, LJ, Millenson, M, O'Donnell, MR, Shami, PJ, Stein, BL, Stone, RM, Thompson, JE, Westervelt, P, Wheeler, B, Shead, DA, and Naganuma, M. "Myelodysplastic syndromes: clinical practice guidelines in oncology." J Natl Compr Canc Netw 11, no. 7 (July 2013): 838-874.

PMID
23847220
Scholars@Duke

Held, LA, Rizzieri, D, Long, GD, Gockerman, JP, Diehl, LF, de Castro, CM, Moore, JO, Horwitz, ME, Chao, NJ, and Gasparetto, C. "A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma." Cancer Invest 31, no. 3 (March 2013): 172-176.

PMID
23406188
Full Text

Morris, TA, DeCastro, CM, Diehl, LF, Gockerman, JP, Lagoo, AS, Li, Z, Moore, JO, Rizzieri, DA, and Rao, AV. "Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia." Leuk Res 37, no. 1 (January 2013): 28-31.

PMID
23046833
Full Text

Hillmen, P, Muus, P, Röth, A, Elebute, MO, Risitano, AM, Schrezenmeier, H, Szer, J, Browne, P, Maciejewski, JP, Schubert, J, Urbano-Ispizua, A, Castro, CD, Socié, G, and Brodsky, RA. "Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria." British Journal of Haematology 162, no. 1 (2013): 62-73.

Full Text

Szer, J, Muus, P, Roeth, A, Elebute, MO, Risitano, AM, Schrezenmeier, H, Maciejewski, JP, Urbano-Ispizua, A, III, DCCM, Socie, G, and Brodsky, RA. "Long-Term Safety of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria." BLOOD 120, no. 21 (November 16, 2012).

Scholars@Duke

Mohanty, BD, and De Castro, CM. "Too many clots for comfort." Am J Med 125, no. 3 (March 2012): 243-245.

PMID
22340919
Full Text

Lanasa, MC, Davis, PH, Datto, M, Li, Z, Gockerman, JP, Moore, JO, DeCastro, CM, Friedman, DR, Diehl, LF, Rehder, C, Cook, H, Daugherty, FJ, Matta, KM, Weinberg, JB, and Rizzieri, D. "Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia." Leuk Lymphoma 53, no. 2 (February 2012): 218-224.

PMID
21827374
Full Text

Rao, AV, Rizzieri, DA, DeCastro, CM, Diehl, LF, Lagoo, AS, Moore, JO, and Gockerman, JP. "Phase I study of dose dense induction and consolidation with gemtuzumab ozogamicin and high dose cytarabine in older adults with AML." Journal of Geriatric Oncology 3, no. 3 (2012): 220-227.

Full Text

Christensen, DJ, Chen, Y, Oddo, J, Matta, KM, Neil, J, Davis, ED, Volkheimer, AD, Lanasa, MC, Friedman, DR, Goodman, BK, Gockerman, JP, Diehl, LF, de Castro, CM, Moore, JO, Vitek, MP, and Weinberg, JB. "SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target." Blood 118, no. 15 (October 13, 2011): 4150-4158.

PMID
21844565
Full Text

Pages